5-hydroxy-2-n,n-dipropylaminotetralin has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonio, T; Dutta, AK; Ghosh, B; Kharkar, P; Reith, ME; Zhen, J | 1 |
| Antonio, T; Dutta, AK; Ghosh, B; Reith, ME | 1 |
2 other study(ies) available for 5-hydroxy-2-n,n-dipropylaminotetralin and Parkinson Disease
| Article | Year |
|---|---|
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Free Radical Scavengers; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Isoquinolines; Locomotion; Mice; Parkinson Disease; Radioligand Assay; Rats; Receptors, Dopamine D2; Receptors, Dopamine D3; Reserpine; Structure-Activity Relationship; Thiazoles | 2010 |
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
Topics: Animals; Disease Models, Animal; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Iron Chelating Agents; Locomotion; Magnetic Resonance Spectroscopy; Male; Neuroprotective Agents; Oxyquinoline; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Structure-Activity Relationship; Tetrahydronaphthalenes | 2010 |